USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
27 Oct 2022 | 02:45 PM GMT

Partnerships between Oncology Digital Health and Life Sciences Companies

Anchored by:

Till Bauer
Global Oncology LCM Strategy Director
MSD

Participants:

Till Bauer Global Oncology LCM Strategy DirectorMSD
Till Bauer
Global Oncology LCM Strategy DirectorMSD
Myles Furnace Chief Commercial OfficerEolas Medical
Myles Furnace
Chief Commercial OfficerEolas Medical
DS
Daniel Sanchez Data Sciences PortfolioJanssen
DS
Daniel Sanchez
Data Sciences PortfolioJanssen
HV
Henri Viertolahti Deputy GMKaiku Health
HV
Henri Viertolahti
Deputy GMKaiku Health
Jamie Kichenbrand Independent ConsultantNHS
Jamie Kichenbrand
Independent ConsultantNHS
Joe Zaccaria Director - Key Accounts, Life SciencesTempus Labs
Joe Zaccaria
Director - Key Accounts, Life SciencesTempus Labs
Krishna Moorthy Senior Lecturer, Consultant SurgeonImperial College London
Krishna Moorthy
Senior Lecturer, Consultant SurgeonImperial College London
Mark Grossman VP of Growth Initiatives & Market PartnersGoMo Health - Engagement that Works
Mark Grossman
VP of Growth Initiatives & Market PartnersGoMo Health - Engagement that Works
Piotr Sokolowski Chief Medtech StrategistS3 Connected Health
Piotr Sokolowski
Chief Medtech StrategistS3 Connected Health
Serdar Gemici CEO & Co-founderAlbert Health
Serdar Gemici
CEO & Co-founderAlbert Health

About this Meeting

In a complex disease area like oncology, treatments usually cause adverse effects that compromise patients' quality of life. Digital health solutions have the potential to benefit patients by reducing symptoms, improving diagnosis, improving quality of life, reducing hospitalizations, and increasing treatment adherence. As a result, it looks like a great opportunity for Life Sciences companies to bundle their products with digital health solutions in order to improve patient outcomes and differentiate themselves from competitors. 

When can these partnerships be beneficial for both Digital Health & Life Sciences companies in oncology? How can we build successful collaborations? Join this session to learn more about:  

  • How can digital health companies identify and select the right Life Sciences company to partner with? And vice versa?  
  • Beyond financial reasons, what are the main drivers for Life Sciences companies to partner with oncology digital health solutions? Are pharma requirements becoming harder to meet? Is the bar higher than before? 
  • How can digital health companies in oncology build successful partnerships with Life Sciences companies?  
  • At what stage have we seen more issues/stoppers in building and implementing successful partnerships in oncology?  
  • What are the learnings from previous partnerships in oncology? What worked and what didn’t work? 
  • What does the future look like? How will Digital Health-Life Sciences partnerships evolve over the next few years?

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.